1372192-35-2

Upstream product

• 1372195-80-6 methyl 4-(N,N-bis(2-(trimethylsilyl)ethoxymethyl)sulfamoyl)-3-(4-(((R)-4-(4-cyanophenoxy)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)butanoate 
• 1372195-78-2 methyl 3-(4-(benzyloxy)phenyl)-4-(N,N-bis(2-(trimethylsilyl)ethoxymethyl)sulfamoyl)butanoate 
• 1372195-58-8 4-(((1S)-1-((tetrahydro-2H-pyran-2-yl)oxy)-2,3-dihydro-1H-inden-4-yl)oxy)benzonitrile 
• 1372195-57-7 ((1S)-1-((tetrahydro-2H-pyran-2-yl)oxy)-2,3-dihydro-1H-inden-4-yl)boronic acid 
• 1372195-55-5 5,5-dimethyl-2-((1S)-1-((tetrahydro-2H-pyran-2-yl)oxy)-2,3-dihydro-1H-inden-4-yl)-1,3,2-dioxaborinane 
• 1372195-53-3 2-(((S)-4-bromo-2,3-dihydro-1H-inden-1-yl)oxy)tetrahydro-2H-pyran 
• 83808-19-9 (1S)-4-bromo-2,3-dihydro-1H-inden-1-ol 

Relevant academic research and scientific papers

CYCLIC AMIDE DERIVATIVE

[Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogues and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (1): (where n is 0 to 2; p is 0 to 4; h is 0 to 3; j is 0 to 3; k is 0 to 2; a ring B is an aryl group or a heteroaryl group; X is O, S, or —NR7—; J1 is —CR11aR11b— or —NR11c—; J2 is —CR12aR12b— or —NR12c—; and R1 to R12c are specific groups), a salt of the compound, or a solvate of the salt or the compound.